The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting growing optimism in the AI-driven precision medicine sector, Cowen & Co has raised its price target for Tempus AI to $71 while maintaining a Buy rating. This upgrade follows a 40% year-over-year growth in the company's data services segment, which reached $87 million in the first quarter of 2026. Additionally, the company has officially scheduled the release of its Q2 2026 financial results for July 30, 2026.
The positive outlook is further supported by robust operational performance, including a 500% surge in Minimal Residual Disease (MRD) testing volume, accelerated by a strategic partnership with Personalis to drive cancer testing adoption. Compared to peers in the bioinformatics space, Tempus AI is showing a faster growth trajectory in non-diagnostic revenue, justifying the valuation hike according to analyst reports. Per market data, the stock's current positioning reflects investor confidence in its data-centric business model.
TEM shares closed at $58.67 (as of July 14, 2026), leaving approximately 21% upside to the new price target. Traders are looking ahead to the Q2 earnings report on July 30 as the next major catalyst to confirm margin sustainability in the data segment. On the macro front, investors are also monitoring the U.S. Monetary Policy Report due on July 10, 2026, which could impact risk appetite across high-growth technology sectors.